LY4064912 + LY4064912 + Placebo + Placebo
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Overweight or Obesity
Conditions
Overweight or Obesity, Healthy
Trial Timeline
Aug 28, 2025 → Nov 1, 2026
NCT ID
NCT07152002About LY4064912 + LY4064912 + Placebo + Placebo
LY4064912 + LY4064912 + Placebo + Placebo is a phase 1 stage product being developed by Eli Lilly for Overweight or Obesity. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07152002. Target conditions include Overweight or Obesity, Healthy.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07152002 | Phase 1 | Recruiting |
Competing Products
20 competing products in Overweight or Obesity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TERN-601 | Terns Pharmaceuticals | Phase 2 | 49 |
| LY3457263 + Tirzepatide + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3305677 + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3537031 + Placebo | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Lisdexamfetamine Dimesylate + Placebo (oral) + Placebo (injection) | Eli Lilly | Phase 2 | 52 |
| Eloralintide + Placebo | Eli Lilly | Phase 3 | 77 |
| LY3437943 + Ethinyl Estradiol + Drospirenone | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Acetaminophen | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Placebo | Eli Lilly | Phase 2 | 52 |
| Eloralintide + Placebo | Eli Lilly | Phase 3 | 77 |
| LY3437943 + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3502970 + Placebo | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Placebo | Eli Lilly | Phase 3 | 77 |
| Eloralintide and Tirzepatide + Eloralintide | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Placebo | Eli Lilly | Phase 3 | 77 |
| LY3541105 + Placebo | Eli Lilly | Phase 1 | 33 |
| Retatrutide + Placebo | Eli Lilly | Phase 2 | 52 |
| LY4167586 + Placebo + LY4167586 | Eli Lilly | Phase 1 | 33 |
| AZD9550 + AZD6234 + Placebo comparator | AstraZeneca | Phase 2 | 52 |
| pramlintide acetate + sibutramine + phentermine + placebo | AstraZeneca | Phase 2 | 52 |